Filter content

Take the quiz: Postmenopausal women have incidence rates as high as ___% after almost a year of exposure to antipsychotic medications, suggesting estrogen may have an antioxidant effect protecting against tardive dyskinesia.

A key change in the way Google displays search results for “addiction treatment” and related terms that was implemented last year has rankled many within the field. Some voiced their concerns, and it appears Google, to some degree, is listening.

Training, consultation, resources and referrals are necessary to assist perinatal care clinicians at the “front line” be able to detect, assess, and treat mood and anxiety disorders and substance use disorders.

Somatically healthy people with major depressive disorder showed a median 2 years’ excess cellular aging, compared with age-matched healthy control subjects, in a study published online in Translational Psychiatry.

Michael Myers, MD, says physicians continue to face pressure to remain silent about mental illness, which leads to hesitancy in seeking help and a worsening of symptoms.

Glenbeigh, a Northeast Ohio-based operator of alcohol and drug addiction and treatment programs, has announced the appointment of Gary Seech as its new president. Seech has been with Glenbeigh for more than 20 years. He has served in a variety of roles, starting as an administrator responsible for…

Seasonal affective disorder (SAD) was most prevalent in patients with early-onset bipolar II disorder, compared with other early-onset mood disorders and healthy control subjects, according to a published study.

A new study from researchers at the University of Pennsylvania has found that Medicaid expansion has been associated with “substantial improvements” in access to medications for the treatment of opioid use disorder for individuals referred to treatment by criminal justice agencies. Still, however,…

Astrocyte brain cells appear to be functionally less supportive of neuronal activity in people with bipolar disorder, according to a study involving human induced pluripotent stem cells.

A Phase II clinical trial conducted in London found that in a select group of patients, doses of psilocybin produced comparable antidepressant effects as escitalopram, a commonly prescribed medication for the treatment of depression. Findings from the study were published this week in the New…